SAEs are typically detected through clinical trials, where subjects are closely monitored for any adverse reactions. Post-marketing, SAEs are tracked via pharmacovigilance systems that collect data from various sources, including healthcare providers, patients, and pharmaceutical companies. Monitoring these events helps in identifying potential risks that might not have been evident during clinical trials.
